



# Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)

Technology appraisal guidance Published: 22 March 2017 nice.org.uk/guidance/ta436 Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)

# **Contents**

Advice	3
Background	4
Information	5

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)

## Advice

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer because no evidence submission was received from Roche for the technology.

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)

# Background

Roche has informed NICE that it does not intend to pursue reimbursement for this indication and, as such, will not be making an evidence submission to NICE for this indication.

NICE has therefore terminated this single technology appraisal.

### Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of bevacizumab for treating epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer. If, after doing this, organisations still wish to consider bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer, they should follow the advice on rational local decision-making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when NICE guidance is unavailable.

NICE will review the position at any point if the company decides that it wants to make a full submission.

ISBN: 978-1-4731-2422-6

### Accreditation

